INTRODUCTION
============

The lipoprotein apolipoprotein E (APOE) is mainly produced in the liver and is involved in cholesterol metabolism. APOE has three isoforms (E2, E3, and Ε4), distinguished by its lipid-binding activity.[@B1] The most common isoform, E3, is considered the normal form. Compared with E3, E2 is defective in receptor-binding activity and is associated with lower low-density lipoprotein (LDL) cholesterol, whereas Ε4 has high binding activity with very-low-density lipoprotein (VLDL) and low binding activity with high-density lipoprotein (HDL). These differences in the function of APOE are determined by two single nucleotide polymorphisms (SNPs) within the *APOE* genes: rs429358 and rs7412.

*APOE* polymorphism due to the two SNPs results in three major alleles (E2, E3, and E4) and six genotypes (E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4). Compared with E3 allele carriers, E4 allele carriers have higher risks of dementia[@B2] and cardiovascular disease,[@B3] while the E2 allele may induce hyperlipidemia in conditions such as diabetes and hypothyroidism and are associated with low risks of neurodegenerative disease.[@B2][@B4] Furthermore, *APOE* polymorphism is associated with longevity. In cross-sectional studies,[@B5] the E4 allele frequency decreased with age, while the Ε3 allele frequency increased; centenarian studies demonstrated similar results.[@B6]

However, the association between *APOE* polymorphism and mortality is inconsistent. In many studies, the E4 allele was associated with high mortality,[@B7][@B8][@B9][@B10][@B11][@B12] whereas the E2 allele was associated with low mortality.[@B7][@B9][@B11] In other studies,[@B13][@B14][@B15][@B16] these associations were not significant. Although several cross-sectional studies have reported associations between *APOE* polymorphism and longevity,[@B17][@B18][@B19] few large-scale cohort studies of Asians have been conducted. Therefore, in this study, the effect of *APOE* polymorphism on mortality was investigated in two, large population-based cohort studies of Asians.

METHODS
=======

Study population
----------------

This study was based on the Dong-gu and Namwon Studies, i.e., prospective cohort studies of risk factors for chronic diseases in Korean adults.[@B20] The Dong-gu Study involved 9,260 participants aged 50 years or over. Among them, participants with missing values and 120 participants with E2/E4 genotypes were excluded; therefore, 9,045 participants were included in our analysis. The Namwon Study involved 10,667 participants aged 45 years or over. Among them, participants with missing values and 111 participants with E2/E4 genotypes were excluded; therefore, 10,350 participants were included in our analysis.

APOE genotyping
---------------

The *APOE* genotyping method has been reported.[@B21] Briefly, genomic DNA was extracted from peripheral blood with the AccuPrep Genomic DNA Extraction Kit (Bioneer, Seoul, Korea) or QIAamp DNA Mini Kit (QIAGEN, Chatsworth, CA, USA), according to the manufacturers\' protocols. *APOE* genotypes were determined as described by Hixson and Vernier, with slight modifications.[@B22] The *APOE* genotypes were categorized as E2 (E2/E2 and E2/E3), E3 (E3/E3), and E4 (E3/E4 and E4/E4). Because the E2 and E4 alleles have counteracting effects, the E2/E4 genotypes were excluded from the analysis.

Ascertainment of deaths
-----------------------

Causes and dates of death were obtained through linkage with data from the National Statistical Office. The date of death was ascertained until December 31, 2017. Events were coded according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10).[@B23] Causes of death were categorized as cardiovascular disease (I20--25 and I60--69), cancer (C00--C96), and others.

Covariates
----------

Information regarding smoking history, alcohol intake, and comorbidities was collected through interviews. Smoking history was coded as never, ex-smoker, or current smoker. Alcohol consumption was coded as nondrinker or drinker. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared based on the weight and height measured in a standing position without shoes. Venous blood samples were collected from the participants following an overnight fast. Serum was separated on-site and stored at --70°C until analysis. Total cholesterol, HDL cholesterol, and triglyceride concentrations were determined using an automatic analyzer (Hitachi-7600; Hitachi, Tokyo, Japan).

Statistical analysis
--------------------

The baseline characteristics of the participants are expressed as the mean ± standard deviation or number (%). To examine differences in covariates across the *APOE* genotypes, a trend test was performed. The triglyceride levels were log-transformed because they did not follow normal distributions. The log-rank test was used to compare differences in Kaplan--Meier survival curves.

Multivariate Cox proportional hazard regression was used to evaluate the association between *APOE* genotype and mortality. Model 1 was adjusted for study site. Model 2 was additionally adjusted for age, gender, BMI, smoking history, and alcohol consumption. Model 3 was additionally adjusted for comorbidities, serum total and HDL cholesterol levels, and log-transformed serum triglyceride levels. In subgroup analyses, a Wald test was used to evaluate the interaction.

Ethics statement
----------------

These two studies were approved by the Institutional Review Board (IRB) of Chonnam National University Hospital (Dong-gu Study, IRB No. I-2008-05-056; Namwon Study, IRB No. I-2007-07-062), and informed consent was obtained from each subject.

RESULTS
=======

[Table 1](#T1){ref-type="table"} presents the participants\' baseline characteristics. The 9,045 participants in the Dong-gu Study were followed for 8.5 ± 1.8 years; among them, 1,070 (11.8%) died during this period. The 10,350 participants in the Namwon Study were followed for 11.5 ± 2.3 years, and 1,399 (13.5%) died during this period. In both studies, the serum triglyceride levels were lowest in participants with the E3 allele, and the serum total cholesterol levels were lowest in participants with the E2 allele. The serum HDL cholesterol level was lowest in participants with the E4 allele. The baseline characteristics of the study population according to the APOE genotypes (E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4) are shown in [Supplementary Tables 1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}.

###### Baseline characteristics of the study population according to apolipoprotein E genotypes
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  Characteristics            Dong-gu Study    Namwon Study                                                                                 
  -------------------------- ---------------- -------------- -------------- -------------- --------------- --------------- --------------- ----------
  Follow-up duration, yr     8.6 ± 1.6        8.5 ± 1.8      8.5 ± 1.8      0.120          11.6 ± 2.3      11.5 ± 2.4      11.5 ± 2.3      0.456
  Gender, men                430 (42.0)       2,578 (39.6)   614 (40.5)     0.608          435 (39.7)      3,016 (39.6)    631 (38.6)      0.514
  Age, yr                    64.9 ± 8.1       65.2 ± 8.2     65.1 ± 8.0     0.380          61.7 ± 7.8      61.6 ± 7.8      61.4 ± 7.7      0.633
  Smoking history                                                           0.964                                                          0.578
                             Never            695 (67.8)     4,447 (68.4)   1,024 (67.5)   693 (63.2)      4,945 (64.9)    1,090 (66.7)    
                             Ex-smoker        216 (21.1)     1,354 (20.8)   329 (21.7)     222 (20.3)      1,510 (19.8)    305 (18.7)      
                             Current smoker   114 (11.1)     703 (10.8)     163 (10.8)     181 (16.5)      1,164 (15.3)    240 (14.7)      
  Alcohol intake                                                            0.078                                                          0.578
                             Non-drinker      533 (52.0)     3,488 (53.6)   841 (55.5)     568 (51.8)      4,011 (52.6)    866 (53.0)      
                             Drinker          492 (48.0)     3,016 (46.4)   675 (44.5)     528 (48.2)      3,608 (47.4)    769 (47.0)      
  BMI, kg/m^2^               24.3 ± 2.9       24.4 ± 3.0     24.2 ± 2.9     0.106          24.2 ± 3.0      24.4 ± 3.1      24.4 ± 3.1      0.088
  Hypertension               365 (35.6)       2,305 (35.4)   541 (35.7)     0.944          220 (20.1)      1,643 (21.6)    366 (22.4)      0.162
  Diabetes                   147 (14.3)       827 (12.7)     194 (12.8)     0.329          80 (7.3)        563 (7.4)       113 (6.9)       0.638
  Triglycerides, mg/dL       153.5 ± 123.2    139.2 ± 96.9   149.8 ± 96.8   \< 0.001       168.1 ± 131.3   153.5 ± 105.0   169.6 ± 132.5   \< 0.001
  Total cholesterol, mg/dL   188.8 ± 38.9     202.8 ± 39.5   203.0 ± 41.1   \< 0.001       176.8 ± 37.0    190.5 ± 36.8    192.8 ± 37.5    \< 0.001
  HDL cholesterol, mg/dL     52.6 ± 12.2      51.8 ± 11.9    49.9 ± 11.7    \< 0.001       48.8 ± 13.0     47.7 ± 11.9     45.5 ± 11.4     \< 0.001

All values are given as number (%) or mean ± standard deviation.

BMI = body mass index, HDL = high-density lipoprotein.

[Fig. 1](#F1){ref-type="fig"} shows the Kaplan--Meier survival curve for the *APOE* alleles. Compared with the E3 allele, the E2 allele was associated with low mortality, and the E4 allele was non-significantly associated with high mortality.

![Kaplan-Meier survival curves for *APOE* genotypes.\
APOE = apolipoprotein E.](jkms-34-e269-g001){#F1}

[Table 2](#T2){ref-type="table"} shows the hazard ratios (HRs) and 95% confidence intervals (CIs) according to *APOE* genotype, with the E3 allele used as the reference. In Model 1, the HR for the E2 allele was 0.86 (95% CI, 0.75--0.99) and that for the E4 allele was 1.05 (95% CI, 0.94--1.16); the respective values were 0.84 (95% CI, 0.74--0.96) and 1.08 (95% CI, 0.97--1.20) in Model 2. To evaluate the mediating effect of lipid profiles, we further adjusted for lipid profiles in Model 3. Consequently, the HR for the E2 allele decreased slightly to 0.80 (95% CI, 0.70--0.92), while that for the E4 allele remained unchanged (HR, 1.08; 95% CI, 0.97--1.20). Compared with the E3/E3 genotype, the HRs of E2/E2, E2/E3, E2/E4, E3/E4, and E4/E4 were 1.00 (95% CI, 0.50--2.01), 0.80 (95% CI, 0.69--0.92), 1.05 (95% CI, 0.74--1.51), 1.09 (95% CI, 0.97--1.21), and 1.01 (95% CI, 0.66--1.55) in Model 3, respectively ([Supplementary Table 3](#S3){ref-type="supplementary-material"}).

###### HR and 95% CI among apolipoprotein E genotypes
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  APOE   Death/person-year   Mortality rate (per 1,000 person-year)   Model 1^a^          Model 2^b^          Model 3^c^
  ------ ------------------- ---------------------------------------- ------------------- ------------------- -------------------
  E2     236/21,546.42       10.95                                    0.86 (0.75--0.99)   0.84 (0.74--0.96)   0.80 (0.70--0.92)
  E3     1,813/142,929.72    12.68                                    1 (reference)       1 (reference)       1 (reference)
  E4     420/31,696.00       13.25                                    1.05 (0.94--1.16)   1.08 (0.97--1.20)   1.08 (0.97--1.20)

HR = hazard ratio, CI = confidence interval.

^a^Study sites were adjusted; ^b^age, gender, body mass index, smoking history, and alcohol consumption were additionally adjusted; ^c^history of hypertension and diabetes, total and high-density lipoprotein cholesterol, and log-transformed triglycerides was additionally adjusted.

[Table 3](#T3){ref-type="table"} shows the HR and 95% CI according to the subgroups. No significant difference was found among the subgroups in the association between *APOE* allele and mortality. The difference in HR among the *APOE* genotypes tended to be greater in the Dong-gu Study than in the Namwon Study. The HRs of the E2 allele were 0.75 (95% CI, 0.61--0.93) and 0.85 (95% CI, 0.71--1.02) in the Dong-gu and Namwon Studies, respectively, while those of the E4 allele were 1.10 (95% CI, 0.94--1.29) and 1.07 (95% CI, 0.93--1.23), respectively. The risk difference according to the *APOE* alleles tended to be greater in women than in men, and greater in participants younger than 65 years than in older participants. In participants younger than 65 years, the HR of the E2 allele was 0.70 (95% CI, 0.52--0.92) and that of the E4 allele was 1.25 (95% CI, 1.03--1.53), whereas in the older participants, the HRs were 0.85 (95% CI, 0.72--0.99) and 1.03 (95% CI, 0.91--1.17) in the E2 and E4 alleles, respectively. The HRs of the E2 allele were 0.80 (95% CI, 0.68--0.95) and 0.80 (95% CI, 0.64--1.00) in men and women, respectively, and those of the E4 allele were 1.04 (95% CI, 0.90--1.19) and 1.15 (95% CI, 0.97--1.36), respectively.

###### Stratified analyses of the association between apolipoprotein E genotype and mortality
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  Subgroup      No. (%)         HR (95% CI)     *P* for interaction   
  ------------- --------------- --------------- --------------------- -------------------
  Study sites                                                         0.620
                Dong-gu Study   9,045 (46.6)    0.75 (0.61--0.93)     1.10 (0.94--1.29)
                Namwon Study    10,350 (53.4)   0.85 (0.71--1.02)     1.07 (0.93--1.23)
  Age, yr                                                             0.688
                \< 65           10,829 (55.8)   0.70 (0.52--0.92)     1.25 (1.03--1.53)
                ≥ 65            8,566 (44.2)    0.85 (0.72--0.99)     1.03 (0.91--1.17)
  Gender                                                              0.324
                Men             7,704 (39.7)    0.80 (0.68--0.95)     1.04 (0.90--1.19)
                Women           11,691 (60.3)   0.80 (0.64--1.00)     1.15 (0.97--1.36)

All models were adjusted for study site, age, gender, body mass index, smoking history, alcohol consumption, history of hypertension and diabetes, total and high-density lipoprotein cholesterol, and log-transformed triglycerides. E3 genotype group was used as a reference.

HR = hazard ratio, CI = confidence interval.

DISCUSSION
==========

In our study, the E2 allele was negatively associated with mortality, while the Ε4 allele was positively, but non-significantly, associated with mortality. There was no mediating effect of serum lipids on this association; unexpectedly, the effect of E2 allele increased slightly.

In previous studies, the association between *APOE* polymorphism and mortality was varied according to the size and age of the study population. The association between the E4 allele and mortality was not significant in small studies or studies with insufficient follow-ups.[@B13][@B14][@B15][@B16] In large studies and studies with sufficient follow-ups,[@B7][@B8][@B10][@B11] the E4 allele was associated with high mortality. Studies with participants with the E4 allele, aged 90 years or older, indicated a significantly higher risk of mortality.[@B9][@B10][@B12] However, despite the large sample size in our study, the E4 allele did not confer a significantly higher mortality risk than the E3 allele.

Previous studies have consistently shown that the E2 allele is associated with a lower risk of death than the E3 allele.[@B7][@B10][@B11] Rajan et al.[@B11] and Rosvall et al.[@B7] reported that this association was significant. In a meta-analysis of centenarians,[@B10] the probability of surviving more than 105 years, or the oldest 0.1 percentile, was significantly higher in those with the E2 genotype compared with those with the E3 genotype. However, in the Danish 1905 Cohort Survey of participants older than 92 years,[@B12] the E2 allele did not indicate a significantly lower mortality rate than the other alleles. The protective effect of the E2 allele is primarily explained by its association with low LDL cholesterol levels.[@B1] However, in our study, contrary to our expectations, the HR strengthened from 0.84 to 0.80, when we adjusted for the lipid profile. In contrast to a previous study using the same dataset as that used in the present study, we reported an association between carotid atherosclerosis and *APOE* polymorphism,[@B24] in which adjusting for the lipid profile attenuated this association.

These discrepancies in the association between *APOE* alleles and mortality in previous studies can be attributed to three factors. First, the genetic influence may depend on age. As mentioned above, the older the study population, the smaller is the effect of E2 and the greater is the effect of E4. Jacobsen et al.[@B9] evaluated changes in the association between the E4 allele and mortality with a follow-up period and reported that the longer the follow-up period, the greater was the HR of the E4 allele. By contrast, in our study, the HR of the E4 allele was higher in the younger groups. Next, the association between *APOE* polymorphism and mortality can vary depending on the *APOE* genotype classification method. The *APOE* genotype can be divided into either E2, E3, and E4 according to the allele type or into E4 carrier and E4 non-carrier according to the E4 carrier type. Previous studies comparing risk differences between E4 carriers and non-carriers[@B8][@B9][@B14] overestimated the risk of the E4 allele because the E4 non-carriers included not only E3 carriers but also E2 carriers, who exhibited a lower mortality risk than the E3 carriers. Finally, the frequency of the E4 allele varies by population and is affected by environmental variables such as latitude and temperature.[@B25] The E4 allele frequency of 14.5%--27.9% has been reported, which is higher than 8.6% in our study.[@B7][@B9][@B11][@B12][@B14][@B15] The statistical power of our study was insufficient to detect an HR of 1.08, which was slightly lower than the HR (1.10 to 1.22) reported in other studies,[@B7][@B10][@B11][@B12] because of the low frequency of the E4 allele. Studies based on Asian populations reported a low E4 allele frequency similar to our study, and the association between the E4 allele and mortality was non-significant.[@B13][@B16]

This is the largest individual study evaluating the association between *APOE* genotypes and mortality, which allows us to assess this association according to *APOE* allele types (E2, E3, or E4). Nevertheless, our study presents several limitations. First, additional genetic information that could affect *APOE* was not included. Although the rs429358 and rs7412 considered in our study affect the function of *APOE*, other DNA positions in the *APOE* may also affect its function.[@B26] Next, because the follow-up period was relatively short in this study, the association between *APOE* and mortality by cause of death could not be determined. Additionally, interactions with variables such as age and gender could not be obtained.

In conclusion, the death risk differed according to the *APOE* polymorphism in Korean adults. The E2 allele was associated with a lower risk of mortality than the E3 allele, whereas the E4 genotype was not associated with mortality in Koreans.
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